Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015)
- PMID: 28993143
- DOI: 10.1016/j.ijantimicag.2017.09.016
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015)
Abstract
The aim of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from patients in the Asia-Pacific (APAC) region with healthcare-associated infections. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 1963 Gram-negative organisms (489 P. aeruginosa and 1474 Enterobacteriaceae) were consecutively collected using a prevalence-based approach from 14 medical centres in the APAC region. Antimicrobial susceptibility testing was performed by broth microdilution method as described by the CLSI and the results were interpreted according to EUCAST and CLSI breakpoint criteria. Ceftolozane/tazobactam [MIC50/90, 0.25/4 µg/mL; 89.2/85.8% susceptible (CLSI/EUCAST)] and meropenem [MIC50/90, ≤0.06/≤0.06 µg/mL; 96.3/96.5% susceptible (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Isolates displayed susceptibility rates to other β-lactam agents ranging from 85.8/81.0% for piperacillin/tazobactam to 74.4/72.7% for cefepime and 72.8/68.1% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates, 3.6% were carbapenem-resistant Enterobacteriaceae (CRE) and 25.6% exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. Ceftolozane/tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/16 µg/mL), but not against isolates with a CRE phenotype (MIC50/90, >32/>32 µg/mL). Ceftolozane/tazobactam was the most potent (MIC50/90, 0.5/4 µg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 90.8% at an MIC of ≤4 µg/mL. Pseudomonas aeruginosa exhibited high rates of susceptibility to amikacin [91.2/89.4% (CLSI/EUCAST)] and colistin [98.4/100.0% (CLSI/EUCAST)]. Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins when tested against Enterobacteriaceae.
Keywords: Asia-Pacific; Ceftolozane/tazobactam; Drug resistance; Enterobacteriaceae; Pseudomonas aeruginosa; Surveillance.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Similar articles
-
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19. J Glob Antimicrob Resist. 2017. PMID: 28735046
-
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009. J Antimicrob Chemother. 2017. PMID: 28165526
-
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17. Microb Drug Resist. 2018. PMID: 29039729
-
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1. Pharmacotherapy. 2015. PMID: 26133315 Review.
-
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Drugs. 2014. PMID: 24352909 Review.
Cited by
-
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.Ann Intensive Care. 2023 Jul 18;13(1):65. doi: 10.1186/s13613-023-01153-6. Ann Intensive Care. 2023. PMID: 37462830 Free PMC article. Review.
-
New β-Lactam-β-Lactamase Inhibitor Combinations.Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.
-
Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018).Infect Drug Resist. 2022 Nov 22;15:6739-6753. doi: 10.2147/IDR.S387097. eCollection 2022. Infect Drug Resist. 2022. PMID: 36444213 Free PMC article.
-
Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa.Pharmaceuticals (Basel). 2023 Aug 30;16(9):1230. doi: 10.3390/ph16091230. Pharmaceuticals (Basel). 2023. PMID: 37765038 Free PMC article. Review.
-
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.Antimicrob Agents Chemother. 2019 May 24;63(6):e02578-18. doi: 10.1128/AAC.02578-18. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30962340 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical